Investigating immune recovery from cytomegalovirus after blood stem cell transplants
Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis
This study is looking at how different treatments for graft-versus-host disease (GVHD) affect your immune system's ability to fight off cytomegalovirus (CMV) infections after a stem cell transplant, so we can find out which methods work best for keeping you healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11006335 on NIH RePORTER |
What this research studies
This research focuses on understanding how different treatments for graft-versus-host disease (GVHD) affect the immune system's ability to recover from cytomegalovirus (CMV) infections after hematopoietic cell transplantation (HCT). The study will compare modern GVHD prophylaxis strategies, such as post-transplantation cyclophosphamide and sirolimus, to traditional methods, assessing their impact on CMV-specific immune responses. By using advanced analytical techniques, the research aims to identify how these treatments influence the body's immune reconstitution and overall health outcomes for patients. Patients may be monitored for their immune responses and the effectiveness of these prophylactic strategies in preventing CMV reactivation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing hematopoietic cell transplantation who are at risk for cytomegalovirus infections.
Not a fit: Patients who are not undergoing hematopoietic cell transplantation or those who do not have a risk of cytomegalovirus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing CMV infections in patients undergoing blood stem cell transplants, enhancing their recovery and overall health.
How similar studies have performed: Other research has shown promising results in understanding immune responses in similar contexts, but this specific approach is relatively novel.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Zamora, Danniel — Fred Hutchinson Cancer Center
- Study coordinator: Zamora, Danniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.